Regulatory T cells and Autoimmune Diseases

Table of Contents

Part I Regulatory T cells and immune system 1. Regulatory T cells and their functions in immune system 2. Regulatory T cells: mechanisms of action 3. Regulatory T cells and autoimmunity 4. Sex differences in regulatory T cells during autoimmune disease Part II Role of regulatory T cells in rheumatic diseases 5. Role of regulatory T cells in pathogenesis and therapeutics of systemic lupus erythematosus 6. Role of regulatory T cells in the pathogenesis and therapeutics of primary Sj�gren’s syndrome 7. Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid arthritis and juvenile idiopathic arthritis 8. Role of regulatory T cells in pathogenesis and therapeutics of psoriatic arthritis 9. Role of regulatory T cells in pathogenesis and therapeutics of spondyloarthritis 10. Role of regulatory T cells in pathogenesis and therapeutics of ankylosing spondylitis Part III Role of regulatory T cells in central nervous system demyelinating autoimmune diseases 11. Role of regulatory T cells in pathogenesis and therapeutics of multiple sclerosis 12. Role of regulatory T cells in the pathogenesis and therapeutics of neuromyelitis optica spectrum disorder Part IV Role of regulatory T cells in peripheral nerve, muscle and neuromuscular autoimmune diseases 13. Role of regulatory T cells in pathogenesis and therapeutics of myasthenia gravis 14. Role of regulatory T cells in pathogenesis and therapeutics of GuillainBarr� syndrome and experimental autoimmune neuritis 15. Role of regulatory T cells in pathogenesis and therapeutics of chronic inflammatory demyelinating polyradiculoneuropathy 16. Role of regulatory T cells in pathogenesis and therapeutics of dermatomyositis and polymyositis Part V Role of regulatory T cells in inflammatory bowel diseases 17. Role of regulatory T cells in pathogenesis and therapeutics of Crohn’s disease and ulcerative colitis 18. Role of regulatory T cells in pathogenesis and therapeutics of celiac disease Part VI Role of regulatory T cells in autoimmune liver diseases 19. Role of regulatory T cells in the pathogenesis and therapeutics of autoimmune hepatitis 20. Role of regulatory T cells in pathogenesis and therapeutics of primary biliary cholangitis and primary sclerosing cholangitis Part VII Role of regulatory T cells in autoimmune thyroid diseases 21. Role of regulatory T cells in pathogenesis and therapeutics of Hashimoto’s thyroiditis 22. Role of regulatory T cells in pathogenesis and therapeutics of Graves’ disease and Graves’ orbitopathy Part VIII Role of regulatory T cells in autoimmune lung and kidney diseases 23. Role of regulatory T cells in pathogenesis and therapeutics of Goodpasture’s syndrome (anti-glomerular basement membrane disease) 24. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune glomerulonephritis (IgA vasculitis and IgA nephropathy) Part IX Role of regulatory T cells in autoimmune skin diseases 25. Role of regulatory T cells in pathogenesis and therapeutics of vitiligo 26. Role of regulatory T cells in pathogenesis and therapeutics of psoriasis 27. Role of regulatory T cells in pathogenesis and therapeutics of atopic dermatitis 28. Role of regulatory T cells in pathogenesis and therapeutics of alopecia areata 29. Role of regulatory T cells in pathogenesis and therapeutics of pemphigus vulgaris and bullous pemphigoid 30. Role of regulatory T cells in pathogenesis and therapeutics of scleroderma (systemic sclerosis) Part X Role of regulatory T cells in autoimmune blood and blood vessel disorders 31. Role of regulatory T cells in pathogenesis and therapeutics of primary antiphospholipid syndrome (Hughes syndrome) 32. Role of regulatory T cells in pathogenesis and therapeutics of Kawasaki disease 33. Role of regulatory T cells in pathogenesis and therapeutics of Beh�et disease 34. Role of regulatory T cells in pathogenesis and therapeutics of immune thrombocytopenia 35. Role of regulatory T cells in pathogenesis and treatment of antineutrophil cytoplasmic antibody-associated vasculitis 36. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune hemolytic anemia Part XI Role of regulatory T cells in autoimmune eye diseases and type 1 diabetes mellitus 37. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune uveitis 38. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune retinopathy 39. Role of regulatory T cell in pathogenesis and therapeutics of type 1 diabetes mellitus Part XII Current challenges and future prospects in research towards regulatory T cells based therapeutics in autoimmune diseases 40. Vaccines induced effects on functioning of regulatory T cells: autoimmune perspective 41. Probiotic interventions for regulatory T cells’ induction in autoimmune diseases 42. CAR Treg-based therapeutics for autoimmune diseases 43. Current challenges and future prospects of regulatory T cells based therapeutics in autoimmune disease

Authors

Mitesh Kumar Dwivedi Assistant Professor of Microbiology, C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University, India.

Mitesh Kumar Dwivedi, PhD, is an assistant professor of microbiology at the C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 63 research papers and 46 book chapters, edited 8 books, and serves as an editorial board member and reviewer of many international journals. He has an h-index of 25 with 2261 citations for his research papers. His research interests include investigation of immunogenetic, autoimmune, and therapeutic aspects of vitiligo, rheumatoid arthritis, sickle cell disease, and the role of probiotics in amelioration of autoimmune diseases. He is a recipient of numerous honors: DST-SERB Core Research Grant (2022), SERB-SIRE International Research Fellowship (2022), Best Researcher Award (2020), INSA Visiting Scientist Award (2019), DST-SERB Early Career Research Award (2018), Young Scientist Awards (2011, 2013, and 2018), and all India rank "32� in CSIR-NET national examination (2011; Life Sciences). He has successfully completed six research projects as principal investigator from national funding agencies: SERB-DST, GUJCOST, UTU, and Neo Sciences & Research Solutions Pvt. Ltd. and guided students for their doctoral and master degrees.

DeLisa Fairweather Director of Translational Research Department Cardiovascular Medicine, Mayo Clinic, USA.

DeLisa Fairweather, PhD, is a professor of medicine and immunology and director of translational research in the Department of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida, studying sex/gender differences in cardiovascular and autoimmune diseases, including myocarditis. Her research has been continuously funded by the National Institutes of Health (NIH), the American Heart Association (AHA), BARDA, and others. She serves on NIH, the Board of the Atwal Clinic and Mayo Clinic Mitochondrial Research Center, and formerly on the Board of the Myocarditis Foundation. She was a leader of the US FDA Mayo-led Expanded Access Program during the COVID-19 pandemic. She has served on the National Academies of Sciences, Engineering, and Medicine (NASEM) committee making recommendations to NIH and Congress on the autoimmune disease portfolio of NIH and on the NASEM committee to examine side effects of COVID-19 vaccines. She is a member of the Scientific Advisory Board for the Autoimmune Registry as well as the Organization for the Study of Sex Differences (OSSD).